Our Methodology: How We Evaluate & Recommend Medical Practice Financing 2026

Why You Can Trust These Ratings

Neuroevidence1.com exists to help neurodivergent entrepreneurs and healthcare practitioners find capital on your terms—not a lender's terms, and not through an auction that sells your data to the highest bidder.

We do not resell your information to a dozen lenders. We don't run your application through a marketplace where you get fifteen calls in forty-eight hours. Instead, we match qualified borrowers to vetted financing partners on a one-to-one basis. Lenders compensate us for the vetted leads we send their way, not for the volume of leads we pipe into the system.

This model removes the incentive to collect and blast your personal and financial information. When you see a recommendation on neuroevidence1.com, it comes from transparent scoring criteria, real 2026 rate benchmarks, and a lender's demonstrated track record with neurodivergent practitioners and small clinical teams.

We also weight neurodiversity-aware underwriting into our scoring. Late neurodiversity diagnoses cost women and economies measurable GDP, according to World Economic Forum research. That cost doesn't stop at employment—it extends to capital access. Practitioners who navigate ADHD, autism, dyslexia, or dyscalculia deserve financing systems that don't default to neurotypical communication styles. We reward lenders who offer phone support, plain-language documents, extended application windows, and underwriters trained to spot capability rather than assume deficit.

---

How We Score

Every lender we review receives a weighted evaluation across five dimensions. The weights sum to 100.

Loan Structure & Terms Fit (25%)
We examine whether the lender offers medical practice acquisition loans, equipment financing, working capital lines of credit, and debt consolidation products that align with real practitioner needs. We score on product breadth, term flexibility, and alignment with 2026 benchmarks: 8–11% APR for SBA 7(a) loans, 12–16% APR for equipment financing, and 18–22% APR for working capital lines. We also check whether the lender publishes amortization windows (60–84 months for equipment, up to 25 years for real estate) and typical down-payment ranges (15–25% for equipment, 20–25% for practice acquisition).

Underwriting Transparency & Speed (20%)
Lenders earn points for publishing their underwriting criteria in plain language. We verify they state upfront: minimum credit scores (640+ FICO typical), debt-service-coverage-ratio thresholds (1.25x minimum), and how many months of bank statements they review (typical range: 2–6 months). We score on approval timelines—5–10 business days for equipment, 30–45 days for SBA 7(a)—and whether origination fees (typical 1–3%) are published or buried. We also reward lenders who explain how they underwrite solo practitioners and group practices differently.

Neurodiversity-Aware Underwriting (20%)
This is where we differentiate. We score on: availability of synchronous support (phone, video), quality of plain-language loan guides and FAQs, published accommodations for neurodivergent borrowers (e.g., extended application windows, ADHD-friendly checklists, reduced documentation surprise), and demonstrated track record. We review marketing and borrower testimonials to assess whether neurodivergent practitioners feel genuinely welcome or treated as edge cases.

Fair Pricing for Credit Profiles (18%)
We compare advertised rates against stated credit-score tiers. Borrowers in the fair-credit range (620–680 FICO) typically face 1–2 percentage-point premiums over 700+ FICO borrowers. We flag lenders whose quoted rates shift unexpectedly or whose fee schedules are conditional. We also verify that rate quotes respect your specific credit profile and practice revenue without inflating costs for the sake of margin.

Data Privacy & No Auction Model (17%)
We score on whether the lender commits not to resell, auction, or broker your application. We examine privacy policies, opt-out mechanisms, and how the lender handles hard inquiries (which typically impact your credit 5–10 points for up to 12 months). Lenders that use soft prequalification inquiries, minimize hard inquiries, and match borrowers one-to-one rank higher than those operating marketplace models.

---

How We Get Paid

Neuroevidence1.com is compensated by lenders whose products appear in our reviews and comparisons. When you qualify for financing through a lender we recommend and that lender funds your loan, we receive a referral fee—typically 1–2% of the funded loan amount.

This means:

• We do not charge you to use our site or to receive recommendations.
• We are not paid based on how many leads we send or how often you get called.
• We are paid only when a borrower we refer actually funds a loan, which incentivizes us to recommend lenders with genuine approval rates and fair terms.
• Our compensation does not vary based on which lender you choose. A referral to Live Oak Bank pays the same structure as a referral to Bank of America—we have no financial reason to steer you toward one over another.

This model aligns our incentive with yours: recommend lenders worth your time, with fair rates and transparent underwriting, or lose borrowers to competitors.

---

Sources

Our evaluations are grounded in real, published data from industry authorities, regulators, and lenders:

• MedMoneyGuide: Physician Practice Loans 2026 Complete Bank Comparison Guide — benchmark rates, typical terms, and lender product comparisons.
• World Economic Forum: How late neurodiversity diagnoses cost women and economies — economic impact and workforce data on undiagnosed and late-diagnosed neurodivergence.
• Deloitte Insights: Neurodiversity in the workplace — organizational and cognitive accommodation frameworks.
• Live Oak Bank: Healthcare Practice Loans — specimen terms, underwriting criteria, and published rates.
• Lendio: A Guide to Medical Practice Loans — product types, typical terms, and borrower scenarios.
• Bank of America: Medical Practice Loans & Financing — institutional lender product architecture and credit requirements.

When we cite a specific term (e.g., "SBA 7(a) rates are 8–11% APR in 2026"), we link the claim to its source. Every rating factor is rooted in published lender criteria or regulatory benchmarks, not speculation.

We also use our acquisition calculator and acquisition financing guide to let you model real scenarios before you apply. Neither tool collects your personal data—they're built to help you self-educate.

---

What Happens Next

If you're ready to explore your options, get a personalized rate quote in 2 minutes—no credit-score impact required. Our matching process uses soft prequalification (not a hard inquiry) to connect you with lenders whose credit tiers and practice profiles align with yours. From there, you control the pace.

Read our acquisition loans guide to understand the terminology and typical approval workflows. If you're deciding between a loan and a line of credit, our acquisition loans vs. lines of credit explainer walks through the tradeoffs. And if you want to stress-test your personal cash flow, our affordability calculator shows what monthly payment fits your revenue model without overstretching your debt-to-income ratio (lenders typically max out at 40–43% of monthly revenue).

For neurodivergent practitioners, the financing landscape doesn't have to feel opaque or hostile. This site exists to prove that lenders can be transparent, and that the right capital partner doesn't resell your data or make you repeat yourself ten times over.